Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by serum bactericidal assay using human complement (hSBA) assay. Group 3 data were presented separately.

Analysis was performed on Per-Protocol Analysis Set 2 (PPAS2) defined for accessing ACYW immune response data for participants who received at least 1 dose of study vaccine and had valid post-vaccination serology result of 2nd year of life, with no major protocol violations. Here, 'Number analyzed' = participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay.

Analysis was performed on PPAS2. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

The hSBA vaccine seroresponse against serogroups A, C, Y, and W was defined as post-vaccination hSBA titers greater than or equal to (>=) 1:16 for participants with pre-vaccination hSBA titers less than (<) 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers >=1:8. Group 3 data were presented separately. Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on Per-Protocol Analysis Set 1 (PPAS1) defined for accessing ACYW immune response data for participants who received at least 1 dose of study vaccine and had valid post-vaccination serology result of infancy (6 months of age) vaccination stage, with no major protocol deviations. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse against serogroups A, C, Y, and W was defined as post-vaccination hSBA titers >=1:16 for participants with pre-vaccination hSBA titers <1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers >=1:8. Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

Geometric mean concentration (GMCs) for PT and FHA were measured by electrochemiluminescent (ECL) assay. Concentration was expressed in terms of titers (1/dilution). Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS2. Data for this outcome measure was not planned to be collected and analyzed for Groups 3 and 4.

GMCs of Anti-rotavirus serum IgA antibodies were assessed using enzyme-linked immunosorbent assay (ELISA). Concentrations were measured in terms of units/milliliter (U/mL). Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Data for this outcome measure was not planned to be collected and analyzed for Groups 3 and 4.

GMCs of anti-pneumococcal antibodies was assessed by electrochemiluminscent (ECL) assay. GMCs of Prevnar 13 serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F were reported. Concentration was expressed in terms of titers (1/dilution). Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Here, 'Number analyzed'=participants with available data for the specified categories. Data for this outcome measure was not planned to be collected and analyzed for Groups 3 and 4.

Percentage of participants with anti-pneumococcal antibody concentrations >=0.35 micrograms per milliliter (mcg/mL) and >=1.0 mcg/mL for Prevnar 13 serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F was reported in this outcome measure. Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Here, 'Number analyzed'=participants with available data for specified categories. Data for this outcome measure was not planned to be collected and analyzed for Groups 3 and 4.

Anti-rotavirus IgA antibodies in human serum was measured by ELISA. Fold-rise was calculated as ratio of post-vaccination titer (i.e., 30 days after 6-months vaccination) to pre-dose titer at age of 2 months (i.e., Day 0). Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Data for this outcome measure was not planned to be collected and analyzed for Groups 3 and 4.

GMTs against anti-measles and anti-rubella antibodies were measured by Bulk Measles immunoglobulin G (IgG) Enzyme Immunoassay (EIA) and anti-mumps antibodies were assessed by ELISA. Titers were expressed in terms of 1/dilution.

Analysis was performed on PPAS2. Here, "overall number of participants analyzed" signifies participants with available data for this outcome measure and 'Number analyzed'=participants with available data for each specified category.

GMCs against Streptococcus pneumoniae polysaccharide (PS) serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F were measured by ECL assay. Concentration was expressed in terms of titers (1/dilution).

Analysis was performed on PPAS2. Here, "overall number of participants analyzed" signifies participants with available data for this outcome measure. Data for this outcome measure was not planned to be collected and analyzed for Groups 3 and 4.

Percentage of participants with anti-pneumococcal antibody concentrations >=0.35 mcg/mL and >=1.0 mcg/mL for Prevnar 13 serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F was reported in this outcome measure.

Analysis was performed on PPAS2. Here, "overall number of participants analyzed" = participants with available data for this outcome measure. Data for this outcome measure was not planned to be collected and analyzed for Groups 3 and 4.

Percentage of participants with anti-measles Ab concentrations >=255 milli-international unit per milliliter (mIU/mL), anti-mumps Ab concentrations: >=10 Ab units/mL, and anti-rubella Ab concentrations >=10 international unit per milliliter (IU/mL) was reported in this outcome measure.

Analysis was performed on PPAS2. Here, "overall number of participants analyzed" = participants with available data for this outcome measure and 'Number analyzed'=participants with available data for each specified category.

Percentage of participants with anti-diphtheria Ab concentrations: >= 0.1 and 1 IU/mL, and anti-tetanus Ab concentrations: >= 0.1 and 1 IU/mL, anti-poliovirus types 1, 2, and 3 Ab titers >= 8 (1/dilution), anti-hepatitis B surface (HBs) antigen Ab concentrations: >= 10 and >= 100 mIU/mL and anti-polyribosyl-ribitol phosphate (anti-PRP) Ab concentrations: >= 0.15 and 1.0 microgram per milliliter (mcg/mL) was reported in this outcome measure.

Analysis was performed on PPAS2. Data for this outcome measure was not planned to be collected and analyzed for Groups 3 and 4. Here, "overall number of participants analyzed" signifies participants with available data for this outcome measure.

Pertussis and FHA vaccine response was defined as: if the pre-vaccination concentration was >=4*lower limit of quantification (LLOQ), then the post-vaccination concentration was >=pre-vaccination concentration and if the pre-vaccination concentration was <4*LLOQ, then the post-booster vaccination concentration was >= 4*LLOQ. The LLOQ was equal to 2.00 Endotoxin units per milliliter (EU/mL).

Analysis was performed on PPAS2. Here, "overall number of participants analyzed" = participants with available data for this outcome measure.

GMCs for PT and FHA were measured by ECL assay. Concentration was expressed in terms of titers (1/dilution). Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Here, "overall number of participants analyzed" = participants with available data for this outcome measure. Data for this outcome measure was not planned to be collected and analyzed for Groups 1 and 2.

Percentage of participants with anti-diphtheria Ab concentrations: >= 0.1 and 1 IU/mL, anti-tetanus Ab concentrations: >= 0.1 and 1 IU/mL, anti-poliovirus types 1, 2, and 3 Ab titers >= 8 (1/dilution), and anti-PRP Ab concentrations: >= 0.15 and 1.0 mcg/mL were reported in this outcome measure. Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Here, 'Number analyzed'=participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Groups 1 and 2.

Pertussis and FHA vaccine response was defined as: if the pre-vaccination concentration was >=4*LLOQ, then the post-vaccination concentration was >= pre-vaccination concentration and if the pre-vaccination concentration was <4*LLOQ, then the post-booster vaccination concentration was >= 4*LLOQ. The LLOQ was equal to 2.00 EU/mL. Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Here, "overall number of participants analyzed" = participants with available data for this outcome measure.

Percentage of participants with anti-hepatitis B surface (HBs) antigen Ab concentrations: >=10 and >=100 mIU/mL was presented in this outcome measure. Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Here, "overall number of participants analyzed" = participants with available data for this outcome measure.

GMCs against anti-measles and anti-rubella antibodies were measured by Bulk Measles IgG EIA, and anti-mumps antibodies were assessed by ELISA. Concentrations were expressed in terms of titers (1/dilution).

Analysis was performed on PPAS2.

Percentage of participants with anti-measles Ab concentrations >=255 mIU/mL, anti-mumps Ab concentrations: >=10 Ab units/mL, and anti-rubella Ab concentrations >=10 IU/mL was reported in this outcome measure.

Analysis was performed on PPAS2.

GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution. Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution. Group 2 data were presented separately. Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Group 2 data were presented separately. Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Fold-rise was calculated as ratio of post-vaccination titer (i.e., 30 days after the 6-months vaccination) to pre-dose titer at 2 months of age (i.e., Day 0). Group 2 data were presented separately. Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution. Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Fold-rise was calculated as ratio of post-vaccination titer (i.e., 30 days after the vaccination at the age of 6 months) to pre-dose titer at Day 0 (i.e., before the first vaccination, at 2 months of age). Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution. Group 2 data were presented separately.

Analysis was performed on PPAS2. Data for this outcome measure was not planned to be collected and analyzed for Group 4. Here, 'Number analyzed'=participants with available data for the specified categories.

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Group 2 data were presented separately.

Analysis was performed on PPAS2. Data for this outcome measure was not planned to be collected and analyzed for Group 4. Here, 'Number analyzed' = participants with available data for each specified category.

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Fold-rise was calculated as ratio of post-vaccination titer (i.e., 30 days after the vaccination at the age of 6 months) to pre-dose titer at Day 0 (i.e., before the first vaccination, at the age of 2 months). Group 2 data were presented separately.

Analysis was performed on PPAS2. Here, 'Number analyzed'=participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

The hSBA vaccine seroresponse against serogroups A, C, Y, and W was defined as post-vaccination hSBA titer >=1:16 for participants with pre-vaccination hSBA titer <1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers >=1:8. Group 2 data were presented separately.

Analysis was performed on PPAS2. Here, 'Number analyzed'=participants with available data for specified categories. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.

Analysis was performed on PPAS2. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay.

Analysis was performed on PPAS2. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Fold-rise was calculated as ratio of post-vaccination titer (i.e., 30 days after the vaccination at the age of 12 months) to pre-dose titer at Day 0 (i.e., before first vaccination, at the age of 2 months).

Analysis was performed on PPAS2. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

The hSBA vaccine seroresponse against serogroups A, C, Y, and W was defined as post-vaccination hSBA titer >=1:16 for participants with pre-vaccination hSBA titer <1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers >=1:8.

Analysis was performed on PPAS2. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by serum bactericidal assay using rabbit complement (rSBA). Titers were expressed in terms of 1/dilution. Group 3 data were presented separately. Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Here, "overall number of participants analyzed" = participants with available data for this outcome measure and 'Number analyzed'=participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by serum bactericidal assay using rabbit complement (rSBA). Titers were expressed in terms of 1/dilution. Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Here, "overall number of participants analyzed" = participants with available data for this outcome measure and 'Number analyzed'=participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by rSBA. Titers were expressed in terms of 1/dilution. Group 3 data were presented separately.

Analysis was performed on PPAS2. Here, "overall number of participants analyzed" = participants with available data for this outcome measure and 'Number analyzed'=participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by rSBA. Titers were expressed in terms of 1/dilution.

Analysis was performed on PPAS2. Here, "overall number of participants analyzed" = participants with available data for this outcome measure and 'Number analyzed'=participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

SR: expected AR (sign/symptom) observed & reported under conditions (nature & onset) prelisted (i.e., solicited) in protocol & CRF. Injection site reactions were tenderness, erythema & swelling. Assessment of injection site reactions after MenACYW Conjugate vaccine, Menveo, Prevnar 13, Hexacima, MMR, Pentaxim & ENGERIX-B allowed local reactogenicity assessment & helped to identify injection site reaction per vaccine received. Here, for Groups (Gps) 2 & 4: "0" in number analyzed for MenACYW vaccine (Vac.) categories signifies that no participant were evaluable; for Gps 1, 3 & 4: "0" in number analyzed for Menveo Vac. categories signifies that no participant were evaluable; for Gps 3 and 4: '0' in number analyzed field of Hexacima Vac. categories signifies that no participant were evaluable; for Gps 1 and 2: '0' in number analyzed field of Pentaxim and ENGERIX-B Vac. categories signifies that no participant were evaluable, as specified vaccines were not administered in specified groups.

Safety analysis set. 'Number analyzed'=participants with available data for each specified category & '0' in number analyzed field of specified age of vaccination (2, 3, 4, 4.5, 6 & 12 months) signifies that no participants received specified category vaccine & thus were not available for analysis. Reported AEs for each arm were presented as pre-specified in protocol & were not planned to be collected for Rotavirus vaccine because it was given orally & no injection site reactions were expected.

A solicited reaction (SR) was an expected adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the case report form (CRF) and considered as related to the product administered. Solicited systemic reactions included fever, vomiting, crying abnormal, drowsiness, appetite lost, and irritability. Reported AEs for each arm were presented as pre-specified in the study protocol.

Analysis was performed on safety analysis set. Here, 'Number analyzed'=participants with available data for each specified category and '0' in the number analyzed field signifies that none of the participants received the specified category vaccination and thus were not available for analysis.

An AE was any untoward medical occurrence in a participant or in a clinical investigation participant administered a medicinal product and which did not had any casual relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination. Reported AEs for each arm were presented as pre-specified in the study protocol.

Analysis was performed on safety analysis set. Here, 'Number analyzed'=participants with available data for each specified category and '0' in the number analyzed field signifies that none of the participants received the specified category vaccination and thus were not available for analysis.

A SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI was an event for which ongoing monitoring and rapid communication by the Investigator to the Sponsor must be done. Such an event might warrant further investigation in order to characterize and understand it. Depending on the nature of the event, rapid communication by the study Sponsor to other parties (e.g, regulators) might also be warranted. Reported AEs for each arm were presented as pre-specified in the study protocol.

Analysis was performed on safety analysis set.

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Percentage of participants with hSBA Titers distribution < 1:4, 1:4 and 1:8 is reported in this outcome measure. Infant series here denotes the vaccines administered at the age of 6 months of participants.

Analysis was performed on PPAS1. Data for this outcome measure was not planned to be collected and analyzed for Group 4.

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Percentage of participants with hSBA Titers distribution < 1:4, 1:4 and 1:8 is reported in this outcome measure.

Analysis was performed on PPAS1. Here, 'Number analyzed'=participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Group 4.